658 related articles for article (PubMed ID: 9189093)
1. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1997 Jun; 84(6):803-7. PubMed ID: 9189093
[TBL] [Abstract][Full Text] [Related]
2. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
4. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
[TBL] [Abstract][Full Text] [Related]
5. [Expression of P53 protein in cutaneous melanoma].
Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M
Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650
[TBL] [Abstract][Full Text] [Related]
6. Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma.
Ferrari D; Lombardi M; Ricci R; Michiara M; Santini M; De Panfilis G
J Cutan Pathol; 2007 Sep; 34(9):705-12. PubMed ID: 17696918
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.
Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA
Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257
[TBL] [Abstract][Full Text] [Related]
8. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.
Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U
J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996
[TBL] [Abstract][Full Text] [Related]
9. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.
Richmond-Sinclair NM; Lee E; Cummings MC; Williamson R; Muller K; Green AC; Hayward NK; Whiteman DC
Melanoma Res; 2008 Oct; 18(5):336-45. PubMed ID: 18781132
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
11. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions.
Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J
Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642
[TBL] [Abstract][Full Text] [Related]
12. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma.
Zhuang L; Scolyer RA; Lee CS; McCarthy SW; Cooper WA; Zhang XD; Thompson JF; Hersey P
Histopathology; 2009 Mar; 54(4):462-70. PubMed ID: 19309398
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
14. Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma.
Ross DA; Laing JH; Sanders R; Wilson GD
Eur J Surg Oncol; 2006 Feb; 32(1):80-4. PubMed ID: 16256294
[TBL] [Abstract][Full Text] [Related]
15. p53 oncoprotein overexpression in choroidal melanoma.
Janssen K; Kuntze J; Busse H; Schmid KW
Mod Pathol; 1996 Mar; 9(3):267-72. PubMed ID: 8685226
[TBL] [Abstract][Full Text] [Related]
16. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
Salti GI; Manougian T; Farolan M; Shilkaitis A; Majumdar D; Das Gupta TK
Cancer Res; 2000 Sep; 60(18):5012-6. PubMed ID: 11016620
[TBL] [Abstract][Full Text] [Related]
17. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
18. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
19. Use of oncogene expression as an independent prognostic marker for primary melanoma.
Grover R; Pacifico MD; Wilson GD; Sanders R
Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057
[TBL] [Abstract][Full Text] [Related]
20. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]